This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (4) Citing Articles via Google Scholar Google Scholar Articles by Fassino, S. Articles by Pierò, A. Search for Related Content PubMed PubMed Citation Articles by Fassino, S. Articles by Pierò, A. Social Bookmarking                   What's this?

Use of Reboxetine in Bulimia Nervosa: A Pilot Study

Department of Neurosciences, Section of Psychiatry, University of Turin, Turin, Italysecondo.fassino{at}unito.it

Giovanni Abbate Daga

Sonia Boggio

Lorenzo Garzaro

Andrea Pierò

Department of Neurosciences, Section of Psychiatry, University of Turin, Turin, Italy

The pharmacological approach to bulimia nervosa is mainly based (BN) on selective serotonin reuptake inhibitors, but many elements suggest the possible involvement of the noradrenergic system in this disorder. The aim of the study was to assess the efficacy of reboxetine – aselective norepinephrine uptake inhibitor – in a sample of bulimicoutpatients, after 3 months of treatment. Twenty-eight of 77consecutively admitted patients with a DSM-IV diagnosis of BN (without Axis I comorbidity) received reboxetine. All patients were assessed at baseline (T0), and after 1 month (T1) and 3 months (T3), respectively, of treatment with reboxetine 4 mg/day. The subjects were administered the following questionnaires: Hamilton Rating Scale for Anxiety (HAM-A) and for Depression (HAM-D), Global Assessment Functioning (GAF), Eating Disorder Inventory-2 (EDI-2) and Body Shape Questionnaire (BSQ). Sixty percent of the patients were responsive to treatment(evaluated as a 50% decrease of bulimic behaviours). After 3 months of treatment, a significant reduction emerged in the scores of various EDI-2 subscales (Bulimia, Drive for Thinness, Body Dissatisfaction, Social Insecurity, Interpersonal Distrust, etc.) and in the BSQ total score. Moreover, depressive symptoms (HAM-D) and Global Functioning (GAF) scores showed a significant improvement. These data support a fast and favourable effect of reboxetine in the treatment of BN, both onsymptoms and psychopathological features. Moreover, the specific and strong action of reboxetine on improvement of social functioning is also supported in this disorder.

Key Words: antidepressants • bulimia nervosa • drug • eating disorders • noradrenaline • pharmacological treatment • reboxetine

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				E. Hazen and M. Fava Successful treatment with duloxetine in a case of treatment refractory bulimia nervosa: a case report J Psychopharmacol, September 1, 2006; 20(5): 723 - 724. [Abstract] [PDF]

				J. Yager, M. J. Devlin, K. A. Halmi, D. B. Herzog, J. E. Mitchell, P. S. Powers, and K. J. Zerbe Eating Disorders Focus, October 1, 2005; 3(4): 503 - 510. [Abstract] [Full Text] [PDF]

				J. Yager, M. J. Devlin, K. A. Halmi, D. B. Herzog, J. E. Mitchell, P. S. Powers, and K. J. Zerbe Guideline Watch: Practice Guideline for the Treatment of Patients With Eating Disorders, 2nd Edition Focus, October 1, 2005; 3(4): 546 - 551. [Full Text] [PDF]